Pearl Bio and Merck partner for discovery of cancer therapies
13 Mar 2024
License out/inAcquisition
Preview
Source: Pharmaceutical Technology
The initial focus of the deal will be on discovering and developing biologic therapies aimed at treating cancer. Credit: Gorodenkoff via Shutterstock.
Synthetic biology company Pearl Bio has signed a licence, partnership and option agreement with Merck for the discovery of biologic therapies that incorporate non-standard amino acids to treat cancer.
The partnership is underpinned by the substantial expertise and patents from its scientific co-founders’ laboratories which focus on the use of genomically recoded organisms (GROs) for encoding synthetic chemistries.
This approach is expected to create new classes of multi-functionalised biologics with adjustable properties.
The alliance will leverage Pearl’s GRO technology, along with its expertise in both cell-based and cell-free systems and the use of tethered ribosomes for encoding synthetic monomers. to target epitopes that were previously inaccessible.
Pearl is entitled to receive $1bn in combined upfront, option and milestone payments from Merck.
See Also:
Preview
Source: Pharmaceutical Technology
The company will receive royalty payments on the sales of any approved products that emerge from the partnership.
Merck Research Laboratories Discovery Biologics vice-president Juan Alvarez stated: “Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries.”
Pearl Bio, supported by Khosla Ventures, focuses on advancing its platform technology to develop multi-functionalised biologics and biomaterials through encoding synthetic chemistries.
The company is expanding its capabilities both in-house and via strategic pharmaceutical collaborations.
The latest development comes after Merck concluded the acquisition of Harpoon Therapeutics for $680m in early 2024, broadening its oncology pipeline.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.